Grant: Doctoral: Vanier Canada Graduate Scholarships
University of Toronto
$150,000.00
Integrating high-throughput technologies for the identification and validation of ovarian cancer biomarkers
EF 2013-14
Résumé
Ovarian cancer is the most lethal gynecological cancer in Canada. When ovarian cancer is diagnosed at early stages, the survival rate for 5 years is close to 90% but 10-30% when they have late stage disease. This is mainly because ovarian cancer has few early or specific symptoms. In our laboratory, we have identified many proteins as potential ovarian cancer markers that could be used in the clinic to diagnose the disease early via a blood test. However, these proteins require further investigation. Thus, we hypothesize that we will be able to identify proteins with the highest potential to be a clinically useful marker through combining different high-throughput approaches. We also hypothesize that we will be able to develop robust quantitative tests for our candidates through combining gold standard methods of quantifying blood components with current high-throughput technologies. This, in turn, will allow for reliable validation of these candidates in a cohort of ovarian cancer patients and healthy controls. In our laboratory, we have pioneered the development of such a test for rapidly verifying markers in blood samples. In the proposed study, we will develop a sound test for the quantification of the candidate markers in a cohort of blood samples. Blood from women with and without ovarian cancer will be examined to see whether our candidate markers are present in only women with cancer. Identifying and characterizing ovarian cancer early can significantly reduce ovarian cancer-related deaths since these blood-based markers could be used routinely to screen patients. There is a clear imbalance between the survival rates of the different ovarian cancer stages, as these rates decrease exponentially in late stage diagnoses. Validation of such blood markers is thus extremely valuable as it will allow for the introduction of a minimally invasive method for detecting early stage cancer.
Programme
Doctoral: Vanier Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
299917
Name
Leung Felix
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Integrating high-throughput technologies for the identification and validation of ovarian cancer biomarkers
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Bioinformatics; Biomarker; Immunoassay; Ovarian Cancer; Proteomic; Serum; Validation
Abstract
Ovarian cancer is the most lethal gynecological cancer in Canada. When ovarian cancer is diagnosed at early stages, the survival rate for 5 years is close to 90% but 10-30% when they have late stage disease. This is mainly because ovarian cancer has few early or specific symptoms. In our laboratory, we have identified many proteins as potential ovarian cancer markers that could be used in the clinic to diagnose the disease early via a blood test. However, these proteins require further investigation. Thus, we hypothesize that we will be able to identify proteins with the highest potential to be a clinically useful marker through combining different high-throughput approaches. We also hypothesize that we will be able to develop robust quantitative tests for our candidates through combining gold standard methods of quantifying blood components with current high-throughput technologies. This, in turn, will allow for reliable validation of these candidates in a cohort of ovarian cancer patients and healthy controls. In our laboratory, we have pioneered the development of such a test for rapidly verifying markers in blood samples. In the proposed study, we will develop a sound test for the quantification of the candidate markers in a cohort of blood samples. Blood from women with and without ovarian cancer will be examined to see whether our candidate markers are present in only women with cancer. Identifying and characterizing ovarian cancer early can significantly reduce ovarian cancer-related deaths since these blood-based markers could be used routinely to screen patients. There is a clear imbalance between the survival rates of the different ovarian cancer stages, as these rates decrease exponentially in late stage diagnoses. Validation of such blood markers is thus extremely valuable as it will allow for the introduction of a minimally invasive method for detecting early stage cancer.
Competitiondate
201311
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Leung, Felix
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~